ReviewFrontiers in oncology2014
Control of the adaptive immune response by tumor vasculature.
Review in Frontiers in oncology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed.
- Regulation of Tumor Vascular Microenvironment by Nestin and Fms-related Tyrosine Kinase 1 (FLT1) and Their Prognostic Significance in Renal Cell Carcinoma.Iranian journal of pathology · 2024Article
- Review
- Renal Carcinoma and Angiogenesis: Therapeutic Target and Biomarkers of Response in Current Therapies.Cancers · 2022Review
- Targeting Angiogenesis in Squamous Cell Carcinoma of the Head and Neck: Opportunities in the Immunotherapy Era.Cancers · 2022Article
- Comprehensive Analysis of HHLA2 as a Prognostic Biomarker and Its Association With Immune Infiltrates in Hepatocellular Carcinoma.Frontiers in immunology · 2022Article
- Overcoming Resistance to Immune Checkpoint Inhibitors in Head and Neck Squamous Cell Carcinomas.Frontiers in oncology · 2021Review
- Strategies to Improve the Antitumor Effect of Immunotherapy for Hepatocellular Carcinoma.Frontiers in immunology · 2021Review
- DKK2 blockage-mediated immunotherapy enhances anti-angiogenic therapy of Kras mutated colorectal cancer.Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · 2020Article
- Anti-angiogenic Agents in Combination With Immune Checkpoint Inhibitors: A Promising Strategy for Cancer Treatment.Frontiers in immunology · 2020Review
- Galectin-1-driven T cell exclusion in the tumor endothelium promotes immunotherapy resistance.The Journal of clinical investigation · 2019Article
- The importance of the vascular endothelial barrier in the immune-inflammatory response induced by radiotherapy.The British journal of radiology · 2018Review
- Vascular Targeting to Increase the Efficiency of Immune Checkpoint Blockade in Cancer.Frontiers in immunology · 2018Review
- Genetic determinants for chemo- and radiotherapy resistance in bladder cancer.Translational andrology and urology · 2017Review
- Radiation-induced changes in the glycome of endothelial cells with functional consequences.Scientific reports · 2017Article
- Fine-Tuning Tumor Endothelial Cells to Selectively Kill Cancer.International journal of molecular sciences · 2017Review
- Immune checkpoint inhibitors: the new frontier in non-small-cell lung cancer treatment.OncoTargets and therapy · 2016Review
- Immunotherapy in Cancer: A Combat between Tumors and the Immune System; You Win Some, You Lose Some.Frontiers in immunology · 2015Review
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
the endothelium is nowadays described as an entire organ that regulates various processesvascular tone, coagulation, inflammation, and immune cell trafficking, depending on the vascular site and its specific microenvironment as well as on endothelial cell-intrinsic mechanisms like epigenetic changes. In this review, we will focus on the control of the adaptive immune response by the tumor vasculature. In physiological conditions, the endothelium acts as a barrier regulating cell trafficking by specific expression of adhesion molecules enabling adhesion of immune cells on the vessel, and subsequent extravasation. This process is also dependent on chemokine and integrin expression, and on the type of junctions defining the permeability of the endothelium. Endothelial cells can also regulate immune cell activation. In fact, the endothelial layer can constitute immunological synapses due to its close interactions with immune cells, and the delivery of co-stimulatory or co-inhibitory signals. In tumor conditions, the vasculature is characterized by an abnormal vessel structure and permeability, and by a specific phenotype of endothelial cells. All these abnormalities lead to a modulation of intra-tumoral immune responses and contribute to the development of intra-tumoral immunosuppression, which is a major mechanism for promoting the development, progression, and treatment resistance of tumors. The in-depth analysis of these various abnormalities will help defining novel targets for the development of anti-tumoral treatments. Furthermore, eventual changes of the endothelial cell phenotype identified by plasma biomarkers could secondarily be selected to monitor treatment efficacy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.